A mother facing a terminal illness has been refused access to a potentially life-saving drug that could have extended her life to witness her daughter’s prom night. Jess Duggan, 44, is making a public appeal for the life-prolonging medication to be accessible through the NHS, providing crucial additional time for terminally ill mothers to spend with their children. She emphasized the urgent need for families not to endure unnecessary suffering, directing her plea to pharmaceutical companies and government officials.
Despite the potential benefits of the Enhertu drug in extending her life, Jess and numerous other women battling breast cancer in England, Wales, and Northern Ireland are being denied access to it, while it is freely available in Scotland and 26 other European countries. Jess, a mother of two from Lewes, East Sussex, shared her distress about the limited time she has left and her desire to create more precious moments with her family, especially for her children, aged 12 and 15.
Expressing regret over missed opportunities due to the delayed availability of Enhertu, Jess expressed frustration at the current situation, highlighting the impact on her family’s future milestones. Breast Cancer Now is pushing for immediate action following changes in NHS drug expenditure policies in April, aiming to facilitate approval for Enhertu, a breakthrough breast cancer treatment.
Jess, who initially fought breast cancer in 2017, has undergone various treatments over the years. However, the recent progression of the disease to her brain and liver has left her with limited treatment options. She remains hopeful about the current chemotherapy but acknowledges the uncertainty surrounding her health. Her advocacy for Enhertu is fueled by the desire to spare other families from similar struggles, emphasizing the necessity for timely access to life-extending treatments.
Breast Cancer Now’s campaign, “Enhertu Now,” underscores the critical need for collaboration between pharmaceutical companies, healthcare authorities, and regulatory bodies to expedite the approval process for Enhertu. The organization’s efforts have garnered significant public support, with over 53,000 signatures on their petition within a short period, underscoring the continued importance of this issue.
As discussions progress to make Enhertu cost-effective and accessible to those in need, the focus remains on providing equitable access to innovative treatments for patients with metastatic breast cancer. The evolving landscape of healthcare policies and collaboration between stakeholders will determine the future availability of Enhertu for individuals battling this devastating disease.